GSK, Pfizer and RSV
RSV vaccines from Pfizer, GSK take another hit with new FDA warning mandate
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare neurological condition that can cause paralysis.
The stock's fall snapped a two-day winning streak.
Texas Attorney General Ken Paxton filed a notice of appeal on Wednesday to continue his lawsuit against Pfizer Inc., for its ...
Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...
From condemning the Jan. 6 Capitol riots to helping fund the President-elect’s impending inauguration, recent years have seen ...
Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...
At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...
UBS lowered the firm’s price target on Pfizer (PFE) to $29 from $31 and keeps a Neutral rating on the shares as part of a broader note on the ...
PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...
The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...
Pfizer (PFE) closed the most recent trading day at $26.91, moving -0.83% from the previous trading session. This change lagged the S&P 500's 0.16% gain on the day. Meanwhile, the Dow experienced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback